ActoGeniX, NV

ActoGeniX is a biopharmaceutical company, focused on the development and commercialization of a new generation of biological drugs; ActoBiotics™. ActoBiotics™ are created using TopAct™, ActoGeniX’s versatile and proprietary technology platform. They can be orally administered and target receptors and pathways in gastrointestinal tissues. This novel class of biopharmaceuticals has the potential to treat a broad range of severe diseases. With several ActoBiotics™ in various stages of clinical and preclinical development, ActoGeniX’s initial focus is on areas with unmet need in gastrointestinal, immunological and metabolic diseases.